ALNY240517C145000
- 3.95
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Alnylam Pharmaceuticals's (NYSE:ALNY) short percent of float has risen 4.82% since its last report. The company recently reported that it has 2.63 million shares sold short, which is 2.39% of all regu
S&P 500 Futures Rise In Premarket Trading; GameStop, Deere Lag
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Chubb Ltd. (CB) was up 8.0% in pre-market trading,
Most Attractive Short-term Overwriting Stocks for June Expiration - Goldman
Goldman Sachs analysts identified short-term overwriting opportunities in large-cap, high implied volatility stocks that do not have earnings events.
S&P 500 Futures Steady In Premarket Trading; Monday.Com, Nextracker Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, monday.com Ltd. (MNDY) was up 19.4% in pre-market t
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | Alnylam Pharmaceuticals Inc : H.c. Wainwright Raises Target Price to $400 From $395
Alnylam Issues 2023 Corporate Responsibility Report
Alnylam Issues 2023 Corporate Responsibility ReportMay 07, 2024– Highlighted New Disclosures of Company's Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy,
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Alnylam Pharma (ALNY) Receives a Hold From Oppenheimer
Express News | Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $225 Price Target
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Express News | Alnylam Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $138 From $136
Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Strong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam Pharmaceuticals